Antioxidant, Antidiabetic, Anticholinergic, and Antiglaucoma Effects of Magnofluorine
Özet
Magnofluorine, a secondary metabolite commonly found in various plants, has pharmacological potential; however, its antioxidant and enzyme inhibition effects have not been investigated. We investigated the antioxidant potential of Magnofluorine using bioanalytical assays with 2,2-azinobis (3-ethylbenzothiazoline-6-sulfonic acid) (ABTS•+), N,N-dimethyl-p-phenylenediamine dihydrochloride (DMPD•+), and 1,1-diphenyl-2-picrylhydrazyl (DPPH•) scavenging abilities and K3[Fe(CN)6] and Cu2+ reduction abilities. Further, we compared the effects of Magnofluorine and butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), α-Tocopherol, and Trolox as positive antioxidant controls. According to the analysis results, Magnofluorine removed 1,1-diphenyl-2-picrylhydrazyl (DPPH) radicals with an IC50 value of 10.58 μg/mL. The IC50 values of BHA, BHT, Trolox, and α-Tocopherol were 10.10 μg/mL, 25.95 μg/mL, 7.059 μg/mL, and 11.31 μg/mL, respectively. Our results indicated that the DPPH· scavenging effect of Magnofluorine was similar to that of BHA, close to that of Trolox, and better than that of BHT and α-tocopherol. The inhibition effect of Magnofluorine was examined against enzymes, such as acetylcholinesterase (AChE), α-glycosidase, butyrylcholinesterase (BChE), and human carbonic anhydrase II (hCA II), which are linked to global disorders, such as diabetes, Alzheimer’s disease (AD), and glaucoma. Magnofluorine inhibited these metabolic enzymes with Ki values of 10.251.94, 5.991.79, 25.411.10, and 30.563.36 nM, respectively. Thus, Magnofluorine, which has been proven to be an antioxidant, antidiabetic, and anticholinergic in our study, can treat glaucoma. In addition, molecular docking was performed to understand the interactions between Magnofluorine and target enzymes BChE (D: 6T9P), hCA II (A:3HS4), AChE (B:4EY7), and α-glycosidase (C:5NN8). The results suggest that Magnofluorine may be an important compound in the transition from natural sources to industrial applications, especially new drugs. © 2022 by the authors.
Anahtar Kelimeler
Tam Kayıt
| Alan | Değer | Dil |
|---|---|---|
| dc.contributor.author | Durmaz, Lokman | |
| dc.contributor.author | Kiziltas, Hatice | |
| dc.contributor.author | Guven, Leyla | |
| dc.contributor.author | Karagecili, Hasan | |
| dc.contributor.author | Alwasel, Saleh | |
| dc.contributor.author | Gulcin, İlhami | |
| dc.date.accessioned | 2026-10-18T20:27:49.745270497Z | |
| dc.date.available | 2026-10-18T20:27:49.745270497Z | |
| dc.date.issued | 2022 | |
| dc.description.abstract | Magnofluorine, a secondary metabolite commonly found in various plants, has pharmacological potential; however, its antioxidant and enzyme inhibition effects have not been investigated. We investigated the antioxidant potential of Magnofluorine using bioanalytical assays with 2,2-azinobis (3-ethylbenzothiazoline-6-sulfonic acid) (ABTS•+), N,N-dimethyl-p-phenylenediamine dihydrochloride (DMPD•+), and 1,1-diphenyl-2-picrylhydrazyl (DPPH•) scavenging abilities and K3[Fe(CN)6] and Cu2+ reduction abilities. Further, we compared the effects of Magnofluorine and butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), α-Tocopherol, and Trolox as positive antioxidant controls. According to the analysis results, Magnofluorine removed 1,1-diphenyl-2-picrylhydrazyl (DPPH) radicals with an IC50 value of 10.58 μg/mL. The IC50 values of BHA, BHT, Trolox, and α-Tocopherol were 10.10 μg/mL, 25.95 μg/mL, 7.059 μg/mL, and 11.31 μg/mL, respectively. Our results indicated that the DPPH· scavenging effect of Magnofluorine was similar to that of BHA, close to that of Trolox, and better than that of BHT and α-tocopherol. The inhibition effect of Magnofluorine was examined against enzymes, such as acetylcholinesterase (AChE), α-glycosidase, butyrylcholinesterase (BChE), and human carbonic anhydrase II (hCA II), which are linked to global disorders, such as diabetes, Alzheimer’s disease (AD), and glaucoma. Magnofluorine inhibited these metabolic enzymes with Ki values of 10.251.94, 5.991.79, 25.411.10, and 30.563.36 nM, respectively. Thus, Magnofluorine, which has been proven to be an antioxidant, antidiabetic, and anticholinergic in our study, can treat glaucoma. In addition, molecular docking was performed to understand the interactions between Magnofluorine and target enzymes BChE (D: 6T9P), hCA II (A:3HS4), AChE (B:4EY7), and α-glycosidase (C:5NN8). The results suggest that Magnofluorine may be an important compound in the transition from natural sources to industrial applications, especially new drugs. © 2022 by the authors. | |
| dc.description.sponsorship | \u0130lhami G\u00FClcin is a member of the Turkish Academy of Sciences (T\u00DCBA). He wants to express his heartfelt gratitude to the T\u00DCBA for their financial assistance. Saleh Alwasel wishes to express his heartfelt gratitude to King Saud University\u2019s Researchers Supporting Project (RSP-2022/59). | |
| dc.identifier.doi | 10.3390/molecules27185902 | |
| dc.identifier.eissn | 1420-3049 | |
| dc.identifier.issn | 1420-3049 | |
| dc.identifier.issue | 18 | |
| dc.identifier.pmcid | PMC9502953 | |
| dc.identifier.pmid | 36144638 | |
| dc.identifier.scopus | 2-s2.0-85138428621 | |
| dc.identifier.startpage | 5902 | |
| dc.identifier.uri | https://rdlopen.rawdatalibrary.net/r/ebyu/12972 | |
| dc.identifier.volume | 27 | |
| dc.identifier.wos | WOS:000856734600001 | |
| dc.language.iso | en | |
| dc.publisher | MDPI | |
| dc.relation.ispartof | Molecules | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.subject | acetylcholinesterase | |
| dc.subject | antioxidant activity | |
| dc.subject | butyrylcholinesterase | |
| dc.subject | carbonic anhydrase | |
| dc.subject | Magnofluorine | |
| dc.subject | phenolic compound | |
| dc.subject | α-glycosidase | |
| dc.subject | alpha-Tocopherol | |
| dc.subject | Antioxidants | |
| dc.subject | Biphenyl Compounds | |
| dc.subject | Butylated Hydroxyanisole | |
| dc.subject | Butylated Hydroxytoluene | |
| dc.subject | Carbonic Anhydrase II | |
| dc.subject | Cholinergic Antagonists | |
| dc.subject | Cholinesterase Inhibitors | |
| dc.subject | Glaucoma | |
| dc.subject | Glycoside Hydrolases | |
| dc.subject | Humans | |
| dc.subject | Hypoglycemic Agents | |
| dc.subject | Molecular Docking Simulation | |
| dc.subject | Picrates | |
| dc.subject | Sulfonic Acids | |
| dc.subject | 1,1-diphenyl-2-picrylhydrazyl | |
| dc.subject | alpha tocopherol | |
| dc.subject | antidiabetic agent | |
| dc.subject | antioxidant | |
| dc.subject | biphenyl | |
| dc.subject | biphenyl derivative | |
| dc.subject | butylcresol | |
| dc.subject | carbonate dehydratase II | |
| dc.title | Antioxidant, Antidiabetic, Anticholinergic, and Antiglaucoma Effects of Magnofluorine | |
| dc.type | Article | |
| dspace.entity.type | Publication | |
| rdl.citation.scopus | 70 | |
| rdl.citation.wos | 69 | |
| rdl.department | Department of Medical Services and Technology, Cayirli Vocational School, Erzincan Binali Yildirim University, Erzincan 24500, Turkey. | |
| rdl.oa.status | gold | |
| rdl.source.index | SCOPUS | |
| rdl.source.index | WOS | |
| rdl.source.index | PUBMED | |
| rdl.wos.index | Science Citation Index Expanded (SCI-EXPANDED) |
